CagriSema is the combination of cagrilintide and semaglutide being studied in Phase 3 clinical trials by Novo Nordisk. It pairs amylin receptor agonism with GLP-1 receptor agonism in a single co-formulation. The research rationale is that the two pathways act through different but complementary mechanisms, producing greater weight reduction than either compound alone.
The Two Components
Semaglutide activates GLP-1 receptors in the pancreas, brain, and gastrointestinal tract. It promotes glucose-dependent insulin secretion, slows gastric emptying, and signals satiety through hypothalamic GLP-1 receptors. Phase 3 trials of semaglutide alone (STEP programme) reported mean body weight reductions of approximately 15% over 68 weeks.
Cagrilintide activates amylin receptors (AMY1–3), which are distributed in different hypothalamic regions than GLP-1 receptors. Amylin receptor activation slows gastric emptying through a distinct mechanism, suppresses postprandial glucagon, and reduces food intake via satiety signalling pathways that GLP-1 does not fully engage.
What the Research Shows
The REDEFINE 1 trial — a Phase 3 study of CagriSema — reported mean weight loss of approximately 22.7% in people with obesity without type 2 diabetes at 68 weeks, compared to approximately 8% for placebo. This exceeded the weight loss seen with semaglutide alone in comparable trials, supporting the hypothesis of additive effects through distinct receptor pathways. The combination also showed improvements in glycaemic markers, blood pressure, and lipid profiles.
Phase 2 data published earlier showed dose-dependent weight reductions ranging from 15% to over 20%, with the combination outperforming each component individually at matched doses.
Research Context
CagriSema represents a broader trend in metabolic research toward multi-receptor targeting. The progression from GLP-1 monotherapy (semaglutide) to dual agonism (tirzepatide: GLP-1 + GIP) to triple agonism (retatrutide: GLP-1 + GIP + glucagon) to amylin combination (CagriSema) reflects growing interest in addressing multiple satiety and metabolic pathways simultaneously.
For researchers studying this combination, FenaLife supplies both cagrilintide and semaglutide as individually Janoshik-verified research compounds. View COAs here.
Frequently Asked Questions
Is CagriSema approved?
As of 2026, CagriSema is in Phase 3 trials. It is not approved for human use. Research-grade components are available for laboratory study only.
Why does the combination outperform each component alone?
GLP-1 and amylin receptors activate different hypothalamic satiety circuits. Combining them engages both pathways, producing additive satiety signalling beyond what either pathway achieves independently.
How does CagriSema compare to retatrutide?
Retatrutide targets GLP-1, GIP, and glucagon receptors. CagriSema combines GLP-1 and amylin receptor activation. Both represent multi-receptor approaches but through different pathway combinations.
For research use only. Not for human consumption, injection, or ingestion.